NAMS — NewAmsterdam Pharma Company N.V. stock price, charts and financials
QT35NewAmsterdam Pharma Company N.V.NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
27.49
-0.30-1.08%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1.65 | Insider Own | 16.98% | Shs Outstand | 116.90M | Perf Week | -6.24% |
| Market Cap | 3.25B | Forward P/E | - | EPS next Y | -1.35 | Insider Trans | -6.94% | Shs Float | 80.70M | Perf Month | -20.98% |
| Enterprise Value | 2.79B | PEG | 2.56 | EPS next Q | - | Inst Own | - | Short Float | 11.37% | Perf Quarter | -2.70% |
| Income | -205.32M | P/S | 143.97 | EPS this Y | -7.56% | Inst Trans | - | Short Ratio | 7.23 | Perf Half Y | -11.61% |
| Sales | 22.56M | P/B | 5.06 | EPS next Y | 24.06% | ROA | -29.04% | Short Interest | 9.18M | Perf YTD | -20.78% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -29.80% | 52W High | 41.75 -34.16% | Perf Year | 23.90% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -32.35% | 52W Low | 20.91 31.46% | Perf 3Y | 137.32% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -39.33% - | Gross Margin | 97.52% | Volatility | 5.90% 5.93% | Perf 5Y | 186.49% |
| Dividend TTM | - | EV/Sales | 123.69 | EPS Y/Y TTM | 35.55% | Oper. Margin | -953.59% | ATR (14) | 1.84 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.76 | Sales Y/Y TTM | 39.13% | Profit Margin | -942.76% | RSI (14) | 36.21 | Recom | 2.10 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.76 | EPS Q/Q | 18.37% | SMA20 | -12.67% | Beta | 0.09 | Target Price | 49.75 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 0.00% | SMA50 | -13.94% | Rel Volume | 0.74 | Prev Close | 27.79 |
| Employees | 100 | LT Debt/Eq | - | Earnings | Aug 05 | SMA200 | -17.90% | Avg Volume | 1.30M | Price | 27.49 |
| IPO Date | Feb 09, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.85% 74.25% | Net Debt/EBITDA | 2.15 | Volume | 956,575 | Change | -1.08% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-20-26 | Initiated | BMO Capital | Outperform | $58 |
| Jul-20-26 | Reiterated | Jefferies | $45 | |
| Jun-30-26 | Reiterated | RBC Capital | Outperform | $47 → $51 |
| Feb-19-26 | Reiterated | Guggenheim | Buy | $45 |
| Jan-21-26 | Reiterated | RBC Capital | Outperform | $47 |
| Jan-06-26 | Reiterated | Leerink Partners | $45 → $55 | |
| Dec-02-25 | Reiterated | Goldman Sachs | Neutral | $37 |
| Oct-20-25 | Reiterated | H.C. Wainwright | Buy | $48 → $52 |
| Aug-25-25 | Initiated | Wells Fargo | Overweight | $45 |
| Mar-03-25 | Reiterated | UBS | $35 → $41 |
Latest News
Jul-29-26
Jul-26-26
Jul-26-2601:59PM
Jul-25-26
Jul-24-26
Jul-24-2610:13AM
Jul-19-26
Jul-19-2603:10AM
Jul-02-26
Jul-02-2608:01PM
Jul-01-26
Jul-01-2608:00AM
Jun-30-26
Jun-30-2611:33AM
Jun-11-26
Jun-11-2610:11AM
Jun-10-26
Company
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 64 | 23 | 46 | 14 | 103 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 64 | 22 | 46 | 14 | 103 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 95 | 106 | 70 | 38 | 20 | 6 | 2 | |
| Research and Development | 144 | 142 | 151 | 159 | 87 | 29 | 5 | |
| Other Operating Expense | -2 | 0 | 1 | 0 | -1 | 0 | 0 | |
| Operating Income | -173 | -226 | -176 | -183 | -4 | -35 | -7 | |
| Interest Expense | 0 | 0 | 0 | 7 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 6 | 22 | -65 | 13 | -19 | -6 | 0 | |
| Net Income Before Taxes | -166 | -204 | -242 | -177 | -23 | -42 | -7 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -166 | -204 | -242 | -177 | -23 | -42 | -7 | |
| Net Income From Continuing Operations | -166 | -204 | -242 | -177 | -23 | -42 | -7 | |
| Net Income | -166 | -204 | -242 | -177 | -23 | -42 | -7 | |
| EPS (Recurring) | -1.65 | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 | |
| EPS (Basic, Before Extraordinaries) | -1.65 | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 | |
| EPS (Diluted) | -1.65 | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 | |
| EBITDA | -192 | -242 | -241 | -177 | -22 | -41 | -7 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 48.54 | 173.87 | 52.52 | 65.42 | 2.01 | — | — | |
| Gross Margin | 100.00 | 95.65 | 100.00 | 100.00 | 100.00 | — | — | |
| Operating Margin | -270.31 | -982.61 | -382.61 | -1,307.14 | -3.88 | — | — | |
| Net Margin | -259.38 | -886.96 | -526.09 | -1,264.29 | -22.33 | — | — | |
| Shares Outstanding | 113 | 114 | 94 | 82 | 19 | 18 | 18 | |
| Market Capitalization | 3,106 | 3,999 | 2,416 | 916 | 207 | 176 | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 '26 | Sale | 30.34 | 105,000 | 3,185,656 | 24,353 | Jul 22 |
| Kooij Louise Frederika | Chief Accounting Officer | Jul 20 '26 | Option Exercise | 11.34 | 105,000 | 1,191,100 | 129,353 | Jul 22 |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 '26 | Option Exercise | 11.28 | 40,000 | 451,000 | 64,353 | Jun 24 |
| Kooij Louise Frederika | Chief Accounting Officer | Jun 22 '26 | Sale | 30.20 | 40,000 | 1,208,159 | 24,353 | Jun 24 |
| Kooij Louise Frederika | Chief Accounting Officer | May 26 '26 | Option Exercise | 10.07 | 65,000 | 654,500 | 89,353 | May 27 |
| Kooij Louise Frederika | Chief Accounting Officer | May 26 '26 | Sale | 35.69 | 65,000 | 2,319,850 | 24,353 | May 27 |
| LANGE LOUIS G | Director | Mar 11 '26 | Sale | 30.42 | 44,619 | 1,357,230 | 10,360 | Mar 12 |
| LANGE LOUIS G | Director | Mar 09 '26 | Option Exercise | 11.50 | 44,619 | 513,119 | 54,979 | Mar 10 |
| LANGE LOUIS G | Director | Mar 06 '26 | Sale | 29.41 | 28,186 | 828,950 | 0 | Mar 10 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 09 '26 | Sale | 30.29 | 101,409 | 3,071,679 | 69,302 | Mar 09 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 09 '26 | Option Exercise | 0.00 | 101,409 | 0 | 170,711 | Mar 09 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 06 '26 | Option Exercise | 0.00 | 94,124 | 0 | 163,426 | Mar 09 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 06 '26 | Sale | 30.32 | 94,124 | 2,853,840 | 69,302 | Mar 09 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 05 '26 | Option Exercise | 0.00 | 104,467 | 0 | 173,769 | Mar 09 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | Mar 05 '26 | Sale | 30.30 | 104,467 | 3,165,350 | 69,302 | Mar 09 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.